Aptose Biosciences (APS) Competitors C$1.58 -0.07 (-4.24%) As of 08/22/2025 04:10 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesBuy This Stock APS vs. ABCN, EMC, FRX, BCT, IPA, TH, ONC, SCYB, COM, and NVHShould you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include VIVO Cannabis (ABCN), Emblem (EMC), Fennec Pharmaceuticals (FRX), BriaCell Therapeutics (BCT), ImmunoPrecise Antibodies (IPA), Theratechnologies (TH), Oncolytics Biotech (ONC), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), and Novoheart (NVH). These companies are all part of the "biotechnology" industry. Aptose Biosciences vs. Its Competitors VIVO Cannabis Emblem Fennec Pharmaceuticals BriaCell Therapeutics ImmunoPrecise Antibodies Theratechnologies Oncolytics Biotech Scythian Biosciences 138267 (COM.TO) Novoheart Aptose Biosciences (TSE:APS) and VIVO Cannabis (CVE:ABCN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation. Which has better earnings and valuation, APS or ABCN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptose BiosciencesN/AN/A-C$154.69M-C$5.02-0.31VIVO CannabisN/AN/AN/AN/AN/A Do analysts rate APS or ABCN? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptose Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00VIVO Cannabis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is APS or ABCN more profitable? Aptose Biosciences' return on equity of 1,017.48% beat VIVO Cannabis' return on equity.Company Net Margins Return on Equity Return on Assets Aptose BiosciencesN/A 1,017.48% -136.29% VIVO Cannabis N/A N/A N/A Do institutionals & insiders have more ownership in APS or ABCN? 15.1% of Aptose Biosciences shares are held by institutional investors. 17.1% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media favor APS or ABCN? In the previous week, Aptose Biosciences' average media sentiment score of 0.00 equaled VIVO Cannabis'average media sentiment score. Company Overall Sentiment Aptose Biosciences Neutral VIVO Cannabis Neutral SummaryAptose Biosciences beats VIVO Cannabis on 5 of the 6 factors compared between the two stocks. Get Aptose Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APS vs. The Competition Export to ExcelMetricAptose BiosciencesBiotechnology IndustryMedical SectorTSE ExchangeMarket CapC$68.03MC$137.09MC$5.76BC$6.37BDividend Yield0.39%3.74%4.41%6.72%P/E Ratio-0.313.8731.1073.11Price / SalesN/A4,057.33433.221,702.25Price / Cash1.6013.1937.7383.29Price / Book-1.7246.309.534.90Net Income-C$154.69M-C$90.99MC$3.26BC$301.20M7 Day Performance-8.14%0.41%2.10%1.35%1 Month Performance-33.61%3.50%2.81%1.88%1 Year Performance-90.06%205.45%30.56%27.39% Aptose Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APSAptose BiosciencesN/AC$1.58-4.2%N/A-90.4%C$68.03MN/A-0.3131Gap UpABCNVIVO CannabisN/AC$1.32+5.6%N/A+0.0%C$256.62MN/A0.00N/AGap UpEMCEmblemN/A$1.88+1.6%N/A+0.0%$245.45M$5.71M-9.89N/AFRXFennec PharmaceuticalsN/AC$12.51-1.5%N/A+53.8%C$241.25MC$34.86M-211.9210Gap UpBCTBriaCell TherapeuticsN/AC$10.60-3.8%C$15.00+41.5%+0.0%C$168.68MN/A-28.195IPAImmunoPrecise AntibodiesN/AC$6.50+0.8%N/A+0.0%C$162.08MC$19.47M-7.3080Gap DownTHTheratechnologiesN/AC$4.46+0.9%N/A+159.5%C$142.30MC$52.22M-50.49103ONCOncolytics Biotech1.7454 of 5 starsC$1.40+19.7%C$3.50+150.0%+9.2%C$107.90MN/A-3.9029Gap UpHigh Trading VolumeSCYBScythian BiosciencesN/AC$3.49-5.9%N/A+0.0%C$102.38MN/A0.00N/AHigh Trading VolumeCOM138267 (COM.TO)N/AN/AN/AN/AC$102.19MN/A0.00N/ANVHNovoheartN/AC$0.53+1.9%N/A+0.0%C$99.98MC$423.50K-13.95N/A Related Companies and Tools Related Companies ABCN Competitors EMC Competitors FRX Competitors BCT Competitors IPA Competitors TH Competitors ONC Competitors SCYB Competitors COM Competitors NVH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:APS) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access